We report a microfluidic device able to control the ejection of fluid through a matrix of out-of-plane microneedles. The device comprises a matrix of open dispensing units connected to needles and filled by a common filling system. A deformable membrane (e.g. in PDMS) is brought into contact with the dispensing units. Pressure exerted on the deformable membrane closes (and thus individualizes) each dispensing unit and provokes the ejection of the dispensing unit content through the outlets. Sufficient pressure over the deformable membrane ensures that all dispensing units deliver a fixed volume (their content) irrespective of the hydrodynamic pressure outside the dispensing unit outlet. The size of the ensemble matrix of dispensing units, the number of liquid reservoirs, as well as the material can vary depending on the considered application of the device or on the conditions of use. In the present paper, the liquid reservoirs are geometrically identical. The geometrical parameters of the device are optimized to avoid as much dead volume as possible, as it was to handle plasmid DNA solutions which are very expensive. The conception, the fabrication and the experimental results are described in this paper. Our prototype is conceived to inject in a uniform way 10 µl of drug through 100 microneedles distributed over 1 cm 2 .
Introduction
For a decade, matrices of microneedles have been proposed as an innovative tool to enhance transdermal drug delivery [1] . Despite the profuse work done to define the geometrical shape of these needles [2] [3] [4] , just a few papers [5] [6] [7] [8] deal with the way to connect these objects to a liquid injection/extraction process. Since these needles are dedicated to injecting or extracting fluids from the skin, a fluidic system is required to handle the liquids.
The simplest way to inject a liquid through a microneedle matrix is to use a single reservoir that is emptied through the whole matrix. This type of system is presented for example in the works of Stoeber [5] . While the liquid should mainly pass through the needles with the lower hydrodynamic resistance, such a system should not permit us to control the quantity of drug that is injected through each needle. Indeed, apart from the fact that the needles are hardly exactly identical, the skin is not a homogeneous material leading to different hydrodynamic resistances at the needle exit. This fact leads to an inhomogeneous injection of the drug into the skin. Another limit of this simple way to inject liquid through microneedles has been pointed out by Stoeber and Liepmann: the system does not allow controlling precisely the amount of injected drug. Consequently, there are two main bottlenecks to face concerning liquid handling: homogeneous spreading through the skin and control of the amount of the injected liquid.
In this paper, we describe a microfluidic system that can be connected to a needle matrix, answering to both the bottlenecks. This work has been done in the framework of a research project dedicated to the gene treatment of skin diseases by means of microneedles (European project ANGIOSKIN, number LSH-2003-512127) . For this kind of treatment, the therapeutical drug has to be equally distributed over the treated skin surface. Furthermore, DNA solutions in these treatments are very expensive and are available only in small quantities. In this context, a distribution system that is able to both manipulate small quantities of fluid with minimal losses was mandatory. The collaboration within the ANGIOSKIN project has constrained several technological choices such as the volume to be injected, or the space encumbrance of the microfluidic system.
Manufacturing a microfluidic distribution system is not a technical challenge. For example, an inkjet printer can provide millions of picoliter ink spots in 1 s. For pharmaceutical use, there are also more specific spotters that are able to manipulate biological fluids such as the VIRTEKs ChipWriterPro. For the delivery of drugs, insulin for the cure of diabetes is nowadays delivered through small needles using micropumps. Since they are painless, microneedles are a logical evolution for those systems. However, only few works propose the integration of a fluidic system with a microneedle matrix. Some works present the adaptation of a microfluidic system with a single needle [6] or with a row of five needles [7] . But as far as we know, no work reported the integration of a microfluidic distribution system with a matrix of out-of-plane microneedles.
We report a simple solution to provide a homogeneous injection through a microneedle matrix with the control of the injected quantity of drug. The idea is to adapt a single drug reservoir over each needle, i.e. a single reservoir is split over as many reservoirs as the number of needles. The reservoirs are covered by a membrane that can deflect under pressure and chase the drug through the needle. The dimensions of the reservoir determine the injected volume and the injection is homogeneous while all the reservoirs are pumped out through each single needle.
System

Description
In order to treat a skin disease by gene therapy, a quantity of about 10-20 µl of DNA solution should be injected uniformly into 1 cm 2 of skin. The system described in this paper is designed to achieve this objective.
The system is made of PDMS, and is composed of 100 individual reservoirs disposed in a matrix. Figure 1 shows a top view of the matrix; the chambers are distributed on 1 cm 2 . They are connected to each other via a network of microchannels in order to allow the filling of the whole system from a single sample of the product. From the entry to the exit, the filling circuit is composed of five parts (figure 1): (i) the inflow reservoir, the drug is brought at the entry of each chamber row (this part is connected to the atmospheric pressure), (ii) the chamber matrix connected by small channels (filling circuit), (iii) hydrodynamic resistances which are added in order to obtain a homogenous filling of the system (details are given below), (iv) the outflow reservoir which is only used to connect all the channels to a single exit and (v) a fluidic diode placed at the connection between the outflow and the pressure reservoir (contained into a box). The pressure reservoir can be tuned either on a negative pressure to fill the microfluidic system, or on a positive pressure to chase out the liquid contained in each reservoir through its corresponding needle. This procedure is detailed further. The diode prevents the drug from flowing back through the filling circuit during injection, i.e., while the pressure is increased in the box in order to deflect the membrane downwards in order to chase the liquid reservoir content through its counterpart needle.
The reservoirs and the filling circuit are covered by a hyperelastic membrane. The mechanical properties of the membrane are chosen to achieve very high deformations in order to pump out a maximum of the chambers content through the needles when it is under pressure. Figure 2 is a picture of the microfluidic system stuck on a silicon needle matrix.
Principle
Due to the system geometry, capillary forces cannot be used to fill it. Indeed, while the liquid enters the chamber from the filling circuit channels, there is a geometrical discontinuity (angle of 90
• in three directions). At this discontinuity, the wetting forces cannot overcome the expansion in three dimensions of the liquid-air interface, and the liquid cannot flow further. Figure 3 shows the filling of the system with capillary forces (left) and suction (right). Due to the capillary forces, only the filling circuit can be filled, including the step which surrounds the top of the chambers (see figure 8 ). By suction (negative pressure in the box, i.e. at the exit of the filling circuit), both the hydrophilic and hydrophobic parts can be filled, but bubbles remain in each chamber in the hydrophilic part. While the liquid primarily covers walls in the hydrophilic case, thus leaving gas bubbles in the reservoirs; with hydrophobic walls, the drug fills completely the chambers before touching the reservoir walls and going further into the filling circuit, in which the ratio surface-bulk is higher. Therefore, we fixed material properties to be hydrophobic and the filling of the microfluidic network is done by suction.
The system is filled from a single drop of the drug. Its volume is the one of the total system volume (i.e. 20 µl). The drop is brought at the entry of the filling circuit by hand. In order to prevent any leak from the chambers to the outlet of the needles, the needles are driven into a soft material in order to close them while filling the chamber matrix (figure 4, left). The drug drop is then sucked into the chamber matrix by means of a reduction of the pressure into the box which is connected to the exit of the filling circuit. The fluidic diode, which is like a trapdoor, is pulled up due to the lower pressure in the box and is therefore open.
The filling circuit is located just under the membrane. It is composed of valves similar to those described by the team of Unger et al [9] . Figure 5 presents its cross-section. During the filling, the membrane deflects upwards and the hydrodynamic resistance of the filling circuit is very low (case 1 in figure 5 ). (1) and opens the filling circuit; during ejection, the pressure pushes the membrane down (2) and closes the connection between chambers. The 60 µm circle corresponds to the microneedle inner diameter for comparison.
When the pressure inside the box is reversed for the ejection of the fluid, the membrane deflects downwards and the valves are closed (case 2 in figure 5 ). This geometry assures that the system behaves like a fluidic circuit during the filling and like a matrix of individual chambers during the ejection, which is one of the cores of the system. The membrane covers and deflects into the inflow reservoir as well. Since the hydrodynamic resistance towards the entrance is very low, the content of this inflow reservoir flows back to the entrance during injection, while the deflection of the membrane inside the channels prevents backflow from the first reservoir row to the inflow reservoir.
For the ejection, the soft material, which closes the needles, is removed and the pressure in the box is increased ( figure 4, right) . This pushes the fluidic diode downwards and closes the filling circuit, the chambers become thus individual units, and while the membrane deflects into the chambers it ejects the drug through the needles. The ejected volume is fixed by the chamber geometry.
It is a single-use system. On one hand, for hygienic reasons, the system cannot be used twice without being sterilized, and on the other hand, after the first use, some drug remains in the system and prevents good filling of it.
Sizing and fabrication
Material
The material used for the system is PDMS. This polymer is easily mouldable at the microscale and has hyperelastic properties. The mechanical properties of this material are very variable. Specifically the shear modulus, which determines the propensity of the membrane to deflect, can vary from 100 kPa to 3 MPa [10] . These mechanical properties depend on several factors such as the proportion of mixed prepolymer and catalyser, the time and temperature into the oven or the brand of the PDMS that is used.
To allow the membrane to have maximal deformation, a low shear modulus is required. This modulus was measured using traction assays. For a mixture of 15 volumes prepolymer for 1 volume catalyser, a shear modulus of 250 kPa (baking 2 h at 70
• C, brand RTV) was measured. For a 10:1 mixture with the same other parameters, the shear modulus was about 400 kPa. Keeping this in mind, we realized the membrane of the system with a 15:1 mixture and the chambers with a 10:1 mixture. Different catalyser ratios help the gluing from one PDMS layer to the other, i.e. the gluing of the membrane on the chambers.
The PDMS is naturally a hydrophobic material. However some surface treatments such as oxygen plasma activation make it temporarily hydrophilic. It is therefore possible to choose the surface properties of the PDMS (hydrophilic versus hydrophobic).
System sizing
Sizing of the system is built on several criteria. First, the size of the chambers is linked to the quantity of the drug that has to be injected and the topology has to prevent from the loss of drug. However, losses are unavoidable and the topology has to permit a good filling of the chambers. A finite element model was done to evaluate the influence of the geometry on the injected volume and on the losses into the system.
The model was built using the COMSOL Multiphysics software. It consists of a single chamber covered by a membrane ( figure 6 ). As the PDMS is a hyperelastic polymer, the model cannot use the standard solid mechanics model that does not include large deformations. Therefore, the neoHookean model was chosen.
This model is an extension of Hooke's law for the case of large deformations; it is useable for plastics and rubber-like 
substances. The model of neo-Hookean solid assumes that the extra stresses due to deformation are proportional to the Finger tensor (1),
where T is the stress tensor, p is the pressure, I is the unity tensor, G is a constant equal to shear modulus and B is the Finger tensor. The strain energy for this model is (2)
where W is potential energy and is the trace (or the first invariant) of Finger tensor B. The neo-Hookean model only needs the shear modulus to characterize the material since the PDMS is supposed to be incompressible. These computations were used as a tool to determine the influence of chamber geometry on losses that have to be minimized and also to get an order of magnitude of the required pressure to apply in order to obtain the expected membrane displacement, which was found to be typically about 1 bar. At a given pressure, there are two parameters that were considered to evaluate the quality of the geometry: the displacement of the membrane and the ratio of the remaining volume of the chamber divided by the volume occupied by the deflected membrane (further noted V i). This parameter has to be minimized since it evaluates losses.
Cylindrical and squared chamber shapes have been tested, and the ratio was almost the same. Figure 7 shows the V i ratio for different pressure and chamber geometry. In this figure, we can see that the most important parameter is the height of the chamber. For pressure above 50 kPa, the ratio is the same for the square (300 × 800 × 800) and the cylindrical (300 × D800) chambers. As soon as a square shape leads to a better compaction (they can have a greater volume than the cylindrical ones when they are arranged in a square matrix of constrained dimensions), all experiments were performed with this geometry. As expected, increasing the shear modulus leads to a lower membrane deflection while the other parameters are set. Therefore, in order to have the smallest V i, we used the lowest shear modulus (250 kPa) to evaluate the geometry efficiency. In addition, a thicker membrane has a lower deflection, and higher chambers are more difficult to empty. Therefore, after fixing a minimal height of the chamber lateral walls (200 µm, due to the fabrication limits) all the surface of the system is occupied by the chambers that are as thin and wide as possible. For the prototype, in which the needles are 1 mm spaced, the chambers have a square shape of 800 µm side length. The thicker these chambers are, the more product the system can inject, but the dead volume goes higher as well.
Furthermore, thanks to the model, we could obtain the evaluation of the membrane deformation shape while it is under pressure. With these data, the height of steps can be adjusted in order to manufacture a pyramidal-like shape, done into the chamber to reduce the dead volume (figure 8).
Fabrication
To manufacture the system, we first made a mould for both the chamber matrix and the filling circuit. Soft photolithography technology with a thick photoresist (SU8) was used [11] . In a first step the wafer is coated with a 100 µm photoresist layer and is further insulated to make the filling circuit; then a second layer of 200 µm or more is coated over the first layer to make the chambers. To obtain a photoresist
(A) ( D) Figure 9 . (A) Mould realization by SU8 photolithography, (B) backing into a press system, (C) gluing on the membrane using an oxygen plasma, (D) removal and cutting of the system, (E) gluing on the microneedle matrix using an oxygen plasma, (F) packaging.
layer as thick as 200 µm, SU82100 is spincoated and baked several times. Each spincoating adds a layer about 100 µm thick. The mould is then developed and CHF3 is deposited on it by a plasma treatment. This treatment makes the removal of PDMS easier after casting. More than two steps of photoresist coating and insulation can be processed in order to achieve a pyramidal structure. The pyramidal structure assures a better sealing of the filling circuit ( figure 5 ) and reduces the dead volume (i.e. liquid that is lost) into the chambers after injection. Usually, the filling circuit is realized in two steps and the chambers in three steps. Figure 9 describes the different manufacturing steps. First, the commercially PDMS prepolymer and catalyser (RTV 615, Bayer silicones) are mixed and deposited on the mould. The PDMS is then degassed under a vacuum to eliminate bubbles created during preparation. To make the chambers pierce the PDMS sheet, the mould is put into a pressing system during backing. In parallel, the membrane is made by spincoating PDMS on a clean wafer. At a speed of 2200 tr min −1 during 30 s, we can realize a 30 µm thick membrane. The fluidic diode is made at this stage. A square of thin paper is put on the system at the place of the diode to prevent the gluing of the membrane. The membrane is then glued on the chambers after being activated by oxygen plasma. The trapdoor is then cut off with a cutter and the paper is removed ( figure 10) .
Lastly, the PDMS system is glued on the microneedles matrix using oxygen plasma activation and the whole system is packed into a box that can be connected to a pressure system. During assembling, care is taken in order to leave the fluid inlet outside the box, while all the microfluidic system is contained into the box (filling circuit, matrix chamber, fluid outlet and fluidic diode).
A microneedles array is fabricated on 4 in diameter, 1000 µm thick silicon wafers. First, a 150 nm thick aluminium masking layer is sputtered and then the S1813 positive photoresist is spincoated on both sides of the wafer. A double-face alignment is realized to pattern both sides. After the frontside UV exposure at 60 mJ cm −1 energy, the photoresist is developed in Micro Ion Free AZ726, aluminium is wet etched with Al etchant and the frontside is protected by a S1813 photoresist layer. The backside is also patterned, the photoresist is developed and aluminium is etched with the same parameters as previously. To finish the preparation of the aluminium masked silicon substrates, the photoresist is removed and the wafers are cleaned by successive acetone and isopropanol baths.
The out-of-plane microneedles are then realized by deep reactive ion etching: we first form around 600 µm depth holes by etching the backside. Then the frontside is processed and around 500 µm length microneedles are formed. Etching parameters are chosen to achieve straight walls and smooth sidewalls in order to improve either microneedles rigidity or surface quality for the microfluidic. To accomplish silicon etching, we carry on backside etching until a helium leak is detected. The final geometrical parameters are 60 µm and 120 µm respectively for the inner and outer diameters.
Results and discussion
Filling
The filling circuit is designed in order to entirely fill all the chambers of the matrix. This objective requires taking care of both the total filling of each individual chamber and the filling of all chambers. Figure 11 shows the filling of a single chamber (while the system walls are hydrophobic). Small bubbles remain in the corners of the chamber; however, the high internal pressure inside those bubbles makes them rapidly be absorbed into the PDMS. For example, the bubble in the high-right corner disappeared in a few seconds. The bigger bubbles disappear within 12 h. However, it is also possible to avoid the formation of these bubbles by filling the chambers from the corners and thus obtain a perfect filling of each chamber ( figure 12 ). While the walls are hydrophobic, when a row of chambers is completely filled until the exit of the filling circuit, the drug will stop to fill the remaining empty chambers. The entire drug will pass through the way already achieved. For this reason, all the chambers must be filled before the drug reaches the exit. However, practically, all the rows of the chambers are not filled at the same speed. This is partially due to small local inhomogeneities in the material properties, but also to the difference of path length for each chamber's row. To assure the complete filling of the matrix, hydrodynamic resistances are added to the end of the filling circuit. Since the liquid has more affinity to fill lower surface/ratio parts, the drug progresses into the hydrodynamic resistances after all the chambers are filled. Figure 13 shows the whole system filling. The system is filled within 4 s at a pressure of 10 kPa.
Ejection
The ejection of ink through the system assembled with a hollowed silicon matrix shows that all chambers have been successfully emptied and shows a good repartition of the drops size ( figure 14) . The mean drop diameter is 625 µm ± 30 µm. However, this test is done under the best condition of use, i.e. the outlet resistance is uniform over all exits (air). This situation is different from the aimed conditions of use, i.e. injection into the skin, for which the outlet resistance is not equal from one needle to the other. Consequently, one may wonder if the system is suitable for ejection while outlet resistances are different from one outlet to the other. For this reason, figure 15 shows the results of an ejection test of ink through a microneedle matrix in which some of the needles are clogged. Indeed, in figure 15 , it is noticeable that the ink did not go through some of the needles (20%). These needles are plausibly clogged, which may have several causes: the needles may not have been completely pierced during the fabrication or impurity may have obstructed the needles during the fabrication process. There is also a possibility that the chambers above these needles were not correctly filled; however, the good filling of the other chambers tend to refute this hypothesis since a chamber which is not filled cannot fill next chambers since they are connected via the filling circuit. Consequently we can assert that due to the presence of a clogged needle, the outlet resistance ranges from zero (air) to infinity (clogged needle), i.e. the worst conditions of use. We can however verify that the ink passes through most of the needles (80%) and that the ejected ink volume is almost the same for each needle (135 nl ± 20 nl) despite the significant difference of resistance at the exit of the needles, ranging from zero (air) to infinity (clogged needle). Even if the ink did not pass through the clogged needles, the content of their reservoirs did not completely flow through the attenant needles. The drop volumes have been optically calculated; assuming that the ink drops are spherical (bubble diameter smaller than capillary length), we can determine their volume from their apparent diameter. Figure 16 shows the distribution of the drop volumes. It is noticeable that 2 drops (over 24 drops) are larger than the other ones; each of these drops is surrounded by three clogged needles and seems to have taken a part of the liquid that should have been ejected through the clogged needles. However, these drops are only 40% bigger than the other ones, which shows that the individualization of the reservoirs works even under the worse conditions (outlet resistance ranging from zero to infinity). The standard deviation for the ejected volume through the other needles (which are surrounded by maximum two clogged needles) is 10 nl.
The system was designed to avoid the loss of the drug as much as possible. When compared to other transdermal administration methods for which only a small amount of the drug passes through the skin [12, 13] , the injection through microneedles has a very high efficiency. The system described in this paper can inject more than 10 µl out of the 20 µl that were used. This amount of losses (about 50%) may still be reduced by improving the geometry of the system. The only unavoidable losses are the volume of the microneedles (10 nl each, i.e. 1 µl in total) and the filling circuit (less than 1 µl). The inflow reservoir for example is a source of losses (about 400 nl) that may be removed for a system with spacial constraints other than that presented in this paper. The inflow reservoir is a thin reservoir (only 100 µm high) which distributes the liquid into the reservoir rows. There exists a method consisting of splitting a channel into two branches and so on, leading to a tree-like structure, however this method is not suitable in our case due to compaction requirements of the Angioskin project.
The control of the quantity and the homogeneity of ejection is achieved in air. However, due to difficulties of piercing the skin with our microneedles, the injection test into the skin could not be done up to now. Skin is not identical from one patient to another, and one can imagine that it may happen that only one (or several) needles did not pierce the skin in clinical use. Consequently, in order to show the robustness of the system, we show results in the worst case: a single matrix containing both hollowed nozzles and clogged ones. In this case, the maximum dispersion is 20%, which is within dermatologists specifications for therapeutic applications. It is further possible to extrapolate that if the system is robust in the worst case, it should be as robust for intermediate cases.
Besides, the injection time within the skin with this system is still not known. While the injection is instantaneous when the needles are not connected to anything, we expect the infusion time within the skin to be longer [14] , probably less than 1 min for an actuation pressure of 1 bar.
Finally, the system has been conceived to handle DNA solutions. Now, making DNA pass through a microchannel is a method to obtain a random fragmentation of it [15] . Therefore electrophoresis tests were done to verify the integrity of DNA molecules after passing through the system. The assays showed that a 7 kbp plasmid DNA did not fractionate under our conditions of use.
Conclusion
A microfluidic distribution system has been designed, fabricated and tested.
We successfully perform the manipulation of small liquid volumes (initial drop of 20 µl) and further inject the liquid through a microneedle matrix with a minimal loss of the drug (about 50% of the used drug). It provides a homogenous injection over the entire matrix and allows controlling the quantity of drug that is injected (120 nl ± 20 nl for each needle, i.e. a total injected volume of about 10 µl), even with a high difference of outlet resistance.
Furthermore, the safe handling of the DNA solution with this system has been verified.
However, the manufacture of the whole system can still be improved. In particular, the making of the diode has to be reconsidered in light of possible commercialization.
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